Lexaria Bioscience Pursuing Regulatory Approvals for DehydraTECH CBD
Lexaria Bioscience Pursuing Regulatory Approvals for DehydraTECH CBD Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. Related: Should You...
Lexaria Bioscience CBD Study Results Expected to Demonstrate Effectiveness Against Hypertension
Lexaria Bioscience CBD Study Results Expected to Demonstrate Effectiveness Against Hypertension Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete...
CURE Pharmaceutical: Should You Buy this Cannabis Biotech Stock?
Should you buy this cannabis biotech stock CURE Pharmaceutical? CURE Pharmaceutical Holding Corp. (OTC: CURR) focuses on the development and manufacturing of drug formulation and drug delivery technologies in novel dosage forms (thin wafers and thin films). Notably,...
Psychedelic Stocks: Nova Mentis Files Genetic Disease Patent
Psychedelic Stocks: Nova Mentis Files Genetic Disease Patent Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based...
Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2
Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent — McMaster University researchers using MediPharm Labs’ CBD50 formula and a CBD:THC 10:2 formulation, which has the same cannabinoid ratio as MediPharm...
CanninPlus with Trading Alerts!
Get advance notice of profitable cannabis & hemp stock trades. Use our machine learning algorithm to start profiting from this explosive industry.
$99 / month after 7-day trial.
Still unsure? Schedule demo at [email protected]
or call 720-254-1374